Shopping Cart 0
Cart Subtotal
USD 0

Toxoplasmosis-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Toxoplasmosis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis-Pipeline Review, H2 2017, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toxoplasmosis-Overview

Toxoplasmosis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Toxoplasmosis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toxoplasmosis-Companies Involved in Therapeutics Development

AbbVie Inc

GlaxoSmithKline Plc

Novartis AG

Sanofi

Turing Pharmaceuticals AG

Toxoplasmosis-Drug Profiles

pyrimethamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silver sulfadiazine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Toxoplasmosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDPK1 for Protozoal Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DHFR for Toxoplasmosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

spiramycin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

toxoplasmosis [type II delta KU80 RH strain] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

toxoplasmosis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

toxoplasmosis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRP-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRP-012-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TUR-006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toxoplasmosis-Dormant Projects

Toxoplasmosis-Product Development Milestones

Featured News & Press Releases

Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee

Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing

Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)

Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary

Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability

Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging

Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction

Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Toxoplasmosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Toxoplasmosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Toxoplasmosis-Pipeline by AbbVie Inc, H2 2017

Toxoplasmosis-Pipeline by GlaxoSmithKline Plc, H2 2017

Toxoplasmosis-Pipeline by Novartis AG, H2 2017

Toxoplasmosis-Pipeline by Sanofi, H2 2017

Toxoplasmosis-Pipeline by Turing Pharmaceuticals AG, H2 2017

Toxoplasmosis-Dormant Projects, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AbbVie Inc

GlaxoSmithKline Plc

Novartis AG

Sanofi

Turing Pharmaceuticals AG

Toxoplasmosis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis-Pipeline Review, H2 2017, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toxoplasmosis-Overview

Toxoplasmosis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Toxoplasmosis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toxoplasmosis-Companies Involved in Therapeutics Development

AbbVie Inc

GlaxoSmithKline Plc

Novartis AG

Sanofi

Turing Pharmaceuticals AG

Toxoplasmosis-Drug Profiles

pyrimethamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silver sulfadiazine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Toxoplasmosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDPK1 for Protozoal Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DHFR for Toxoplasmosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

spiramycin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

toxoplasmosis [type II delta KU80 RH strain] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

toxoplasmosis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

toxoplasmosis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRP-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRP-012-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TUR-006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toxoplasmosis-Dormant Projects

Toxoplasmosis-Product Development Milestones

Featured News & Press Releases

Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee

Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing

Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)

Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary

Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability

Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging

Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction

Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Toxoplasmosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Toxoplasmosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Toxoplasmosis-Pipeline by AbbVie Inc, H2 2017

Toxoplasmosis-Pipeline by GlaxoSmithKline Plc, H2 2017

Toxoplasmosis-Pipeline by Novartis AG, H2 2017

Toxoplasmosis-Pipeline by Sanofi, H2 2017

Toxoplasmosis-Pipeline by Turing Pharmaceuticals AG, H2 2017

Toxoplasmosis-Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

AbbVie Inc

GlaxoSmithKline Plc

Novartis AG

Sanofi

Turing Pharmaceuticals AG